Published by The Buxton Advertiser on Saturday 25 August 2012
A NEW dedicated Breast and Gynaecology Unit is set to open at Macclesfield District General Hospital.
The new purpose-built unit, which opens on September 3, will provide high quality services for the diagnosis, screening and treatment of breast cancer and outpatient facilities for a wide range of gynaecology problems, with the latest equipment and techniques all under one roof.
There will be five consultation rooms, two rooms dedicated to digital mammography and a further two rooms for breast ultrasound in the new unit.
via New unit at hospital – Health – Buxton Advertiser.
A blood test could help predict breast cancer survival. More – click here >>
This week read our clinical article on meningitis, a serious condition where prompt diagnosis and treatment improve both morbidity and mortality. To read more on this article click here >>
The European Medicines Agency has granted marketing authorisation for Signifor, an orphan medicine, used for treating Cushing’s disease when surgery has failed. To read more on this article click here >>
At least seven models are commonly used to evaluate cardiovascular risk. A systematic review of comparative studies in the BMJ investigates which has the best prognostic performance. To read more on this article click here >>
Assessment of the relationship between adherence with antiemetic drug therapy and control of nausea and vomiting in breast cancer patients receiving anthracycline-based chemotherapy
Source: Journal of Managed Care Pharmacy
Background: There are few prevalence data in the literature on nonadherence to outpatient antiemetic regimens for prophylaxis of chemotherapy-induced nausea and vomiting (CINV). It is unclear whether adherence with outpatient antiemetic regimens is associated with better CINV control. Our previous survey research supports the work of clinical pharmacists in collaborative practice with medical oncologists in improving adherence with antiemetic therapy in women undergoing highly emetic chemotherapy for breast cancer. Continue reading
Editorial: HER2 testing in patients with breast cancer
This editorial discusses HER2 testing in relation to the use of HER2 targeted drugs for breast cancer. The author comments,” However, to allow proper use of HER2 targeted drugs, results from HER2 testing need to be available in a timely manner. A recent survey of surgeons in the United Kingdom found, worryingly, that only half of patients with invasive cancer had a HER2 result available when treatment was initially discussed”.
Cohort study: Diabetes, metformin, and breast cancer incidence among postmenopausal women
There is emerging evidence suggesting that metformin may reduce breast cancer incidence, but reports are mixed and few provide information on tumour characteristics. This study used data from the Women’s Health Initiative (WHI) clinical trials to examine relationships among diabetes, metformin use, and breast cancer in postmenopausal women. The WHI clinical trials program involves more than 68,019 postmenopausal women who were observed prospectively; 11,290 had diabetes at study entry or developed it during follow-up, and 3,273 developed invasive breast cancer after study entry. The researchers found that compared with that in women without diabetes, breast cancer incidence in women with diabetes differed by diabetes medication type (P = 0.04). Women with diabetes receiving medications other than metformin had a slightly higher but not statistically significant incidence of breast cancer (hazard ratio [HR], 1.16; 95% CI, 0.93 to 1.45), and women with …
‘Improving outcomes in head and neck cancers: Evidence Update May 2012’ https://www.evidence.nhs.uk/nhs-evidence-content/evidence-updates focuses on a summary of selected new evidence relevant to NICE cancer services guidance ‘Improving outcomes in head and neck cancers’ (2004).
‘Familial breast cancer: Evidence Update May 2012’ (https://www.evidence.nhs.uk/nhs-evidence-content/evidence-updates) focuses on a summary of selected new evidence relevant to NICE clinical guideline 41 ‘The classification and care of women at risk of familial breast cancer in primary, secondary and tertiary care’ (2006).
In producing the Evidence Updates almost 4,000 pieces of evidence were identified. An Evidence Update Advisory Group, comprised of subject experts, has reviewed the prioritised evidence and provided a commentary.
By producing Evidence Updates, NHS Evidence seeks to reduce the need for individuals, managers and commissioners to search for new evidence and to inform guidance developers of new evidence in their field.